Literature DB >> 14981775

Role of complement in neutralization of respiratory syncytial virus.

Sandra M Yoder1, Yuwei Zhu, Mine R Ikizler, Peter F Wright.   

Abstract

Serum neutralizing antibody titers to respiratory syncytial virus (RSV) are higher when assayed with guinea pig complement. A number of different mechanisms have been suggested for enhancement of neutralization by complement. The most straightforward is that complement-antibody complexes present a greater steric hindrance to viral entry than with antibody alone. To define the implications of measuring serum neutralizing antibody with and without complement, sera from adults, young children, infants, and cord bloods were run in plaque neutralization assays with representative viruses of the RSV A and B subgroups. Although titers of neutralizing antibody were higher in the presence of complement, the addition of complement did not increase the ability to detect antibody rises after natural infection. Some of the complement effect may be attributable to an inhibition of RSV replication by complement alone. While these observations do not address the role for complement in the pathogenesis of RSV infection, they suggest that neutralization assays performed without complement may be most reflective of physiologic conditions in the respiratory tract. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14981775     DOI: 10.1002/jmv.20046

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  17 in total

1.  Enhanced Neutralizing Antibody Response Induced by Respiratory Syncytial Virus Prefusion F Protein Expressed by a Vaccine Candidate.

Authors:  Bo Liang; Sonja Surman; Emerito Amaro-Carambot; Barbora Kabatova; Natalie Mackow; Matthias Lingemann; Lijuan Yang; Jason S McLellan; Barney S Graham; Peter D Kwong; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2015-07-08       Impact factor: 5.103

2.  Evaluation of pneumonia virus of mice as a possible human pathogen.

Authors:  Linda G Brock; Ruth A Karron; Christine D Krempl; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2012-03-21       Impact factor: 5.103

3.  Packaging and Prefusion Stabilization Separately and Additively Increase the Quantity and Quality of Respiratory Syncytial Virus (RSV)-Neutralizing Antibodies Induced by an RSV Fusion Protein Expressed by a Parainfluenza Virus Vector.

Authors:  Bo Liang; Joan O Ngwuta; Richard Herbert; Joanna Swerczek; David W Dorward; Emerito Amaro-Carambot; Natalie Mackow; Barbora Kabatova; Matthias Lingemann; Sonja Surman; Lijuan Yang; Man Chen; Syed M Moin; Azad Kumar; Jason S McLellan; Peter D Kwong; Barney S Graham; Anne Schaap-Nutt; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2016-10-14       Impact factor: 5.103

4.  Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera.

Authors:  Joan O Ngwuta; Man Chen; Kayvon Modjarrad; M Gordon Joyce; Masaru Kanekiyo; Azad Kumar; Hadi M Yassine; Syed M Moin; April M Killikelly; Gwo-Yu Chuang; Aliaksandr Druz; Ivelin S Georgiev; Emily J Rundlet; Mallika Sastry; Guillaume B E Stewart-Jones; Yongping Yang; Baoshan Zhang; Martha C Nason; Cristina Capella; Mark E Peeples; Julie E Ledgerwood; Jason S McLellan; Peter D Kwong; Barney S Graham
Journal:  Sci Transl Med       Date:  2015-10-14       Impact factor: 17.956

5.  Attenuated Human Parainfluenza Virus Type 1 Expressing the Respiratory Syncytial Virus (RSV) Fusion (F) Glycoprotein from an Added Gene: Effects of Prefusion Stabilization and Packaging of RSV F.

Authors:  Xiang Liu; Bo Liang; Joan Ngwuta; Xueqiao Liu; Sonja Surman; Matthias Lingemann; Peter D Kwong; Barney S Graham; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

6.  Murine Pneumonia Virus Expressing the Fusion Glycoprotein of Human Respiratory Syncytial Virus from an Added Gene Is Highly Attenuated and Immunogenic in Rhesus Macaques.

Authors:  Linda G Brock; Xiang Liu; Bo Liang; Matthias Lingemann; Xueqiao Liu; Richard Herbert; Ashley D Hackenberg; Ursula J Buchholz; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2018-08-16       Impact factor: 5.103

7.  Effects of Alterations to the CX3C Motif and Secreted Form of Human Respiratory Syncytial Virus (RSV) G Protein on Immune Responses to a Parainfluenza Virus Vector Expressing the RSV G Protein.

Authors:  Bo Liang; Barbora Kabatova; Juraj Kabat; David W Dorward; Xiang Liu; Sonja Surman; Xueqiao Liu; Annie Park Moseman; Ursula J Buchholz; Peter L Collins; Shirin Munir
Journal:  J Virol       Date:  2019-03-21       Impact factor: 5.103

8.  A Single-Dose Recombinant Parainfluenza Virus 5-Vectored Vaccine Expressing Respiratory Syncytial Virus (RSV) F or G Protein Protected Cotton Rats and African Green Monkeys from RSV Challenge.

Authors:  Dai Wang; Shannon Phan; Daniel J DiStefano; Michael P Citron; Cheryl L Callahan; Lani Indrawati; Sheri A Dubey; Gwendolyn J Heidecker; Dhanasekaran Govindarajan; Xiaoping Liang; Biao He; Amy S Espeseth
Journal:  J Virol       Date:  2017-05-12       Impact factor: 5.103

9.  Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following Respiratory Syncytial Virus vaccination and infection.

Authors:  Sandra Fuentes; Roberta L Crim; Judy Beeler; Michael N Teng; Hana Golding; Surender Khurana
Journal:  Vaccine       Date:  2013-06-04       Impact factor: 3.641

Review 10.  Complement and its role in protection and pathogenesis of flavivirus infections.

Authors:  Panisadee Avirutnan; Erin Mehlhop; Michael S Diamond
Journal:  Vaccine       Date:  2008-12-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.